PriceTargets.com logo

NervGen Pharma - NGENF Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.55 As of 04/26/2024 01:00 AM ET
▲ +0.05 (3.33%)

This chart shows the closing price for NGENF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NervGen Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NGENF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NGENF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for NervGen Pharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.55.

This chart shows the closing price for NGENF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in NervGen Pharma. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/13/2021Industrial Alliance SecuritiesInitiated CoverageBuyC$6.00
7/13/2021iA FinancialInitiated CoverageSpeculative Buy$6.00
10/20/2020Maxim GroupReiterated RatingBuy$4.00
8/21/2020Maxim GroupReiterated RatingBuy
(Data available from 4/26/2019 forward)

News Sentiment Rating

1.06 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

NervGen Pharma logo
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.
Read More

Today's Range

Now: $1.55
Low: $1.50
High: $1.58

50 Day Range

MA: $1.90
Low: $1.43
High: $2.60

52 Week Range

Now: $1.55
Low: $1.10
High: $2.99

Volume

50,284 shs

Average Volume

70,734 shs

Market Capitalization

$95.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of NervGen Pharma?

The following sell-side analysts have issued reports on NervGen Pharma in the last twelve months:
View the latest analyst ratings for NGENF.

What is the current price target for NervGen Pharma?

0 Wall Street analysts have set twelve-month price targets for NervGen Pharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for NervGen Pharma in the next year.
View the latest price targets for NGENF.

What is the current consensus analyst rating for NervGen Pharma?

NervGen Pharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for NGENF.

What other companies compete with NervGen Pharma?

Other companies that are similar to NervGen Pharma include Ampliphi Biosciences, Biopharmx, Kinnate Biopharma, NGM Biopharmaceuticals and Cybin. Learn More about companies similar to NervGen Pharma.

How do I contact NervGen Pharma's investor relations team?

NervGen Pharma's physical mailing address is 21-1344 SUMMER ST., HALIFAX A5, B3H 0A8. The company's listed phone number is (778) 731-1711. The official website for NervGen Pharma is www.nervgen.com. Learn More about contacing NervGen Pharma investor relations.